Viamet announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to VT-1598 for the treatment of coccidioidomycosis or Valley Fever, a common lung infection in the southwestern US.
VT-1598 has demonstrated significantly greater potency than fluconazole against Coccidioides isolates in preclinical studies. In addition, oral VT-1598 has also demonstrated high efficacy in treating Coccidioides disease disseminated to the central nervous system. It also exhibits potent activity against other endemic fungi, including Histoplasma and Blastomyces species.
VT-1598 is a selective, oral inhibitor of fungal CYP51.
For more information visit Viamet.com.